LSHTM study reveals gaps in EU pandemic preparedness

23 April 2006

A report published in the on-line version of The Lancet on April 20 says that "considerable gaps exist among European national pandemic plans." Taken from the London School of Hygiene and Tropical Medicine study of European pandemic preparedness, this concluded that further implementation is required to allow national governments to effectively respond.

The LSHTM report considered the pandemic management initiatives in all 25 European Union member states, as well as in Bulgaria, Norway, Romania and Sweden, specifically assessing: planning and coordination; surveillance; public health control measures such as vaccine and antiviral stocks; and health system response and communication. The assessment found that the completeness score of the plans across the EU ranged from 24% to 80%, with an average of 54%.

The research group added that it had only considered plans that were effective as of November 2005, and that action taken after this date may address some of the issues raised in its study.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight